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Designing theranostic nanocarriers with high protein payload and multimodality tracking without cross
interferences between the different imaging probes and the delicate protein cargo is challenging. Here,
chemical modifications of poly(lactic-co-glycolic acid) (PLGA) to produce nanocapsules (NCs) that incor-
porate several imaging moieties are reported. The biocompatible and biodegradable PLGA-NCs can be
endowed with a magnetic resonance imaging (MRI) reporter, two fluorescence imaging probes (blue/NIR)
and a positron emission tomography (PET) reporter. The modular integration of these imaging moieties
into the shell of the NCs is successfully achieved without affecting the morphochemical properties of the
nanocarrier or the protein loading capacity. In vivo biodistribution of the NCs is monitored by MRI, PET
and NIRF and the results from different techniques are analyzed comparatively. The viabilities of two
different human endothelial cells in vitro show no toxicity for NC concentration up to 100 μg mL−1. The
morbidity of mice for 2 weeks after systemic administration and the hepatic/pancreatic enzymes at the
plasma level indicate their in vivo biosafety. In summary, the new theranostic PLGA nanoplatform pre-
sented here shows versatile in vitro/in vivo multimodal imaging capabilities, excellent biosafety and over
1 wt% protein loading.
Introduction
Drug delivery nanocarriers can be extremely advantageous to
administer insoluble, sensitive or multi-component drugs by
protecting the encapsulated therapeutic molecules from clear-
ance, inactivation or degradation, as well as by reducing poten-
tial toxicity, increasing blood circulation time or tissue
specificity.1–5 Poly(lactic-co-glycolic acid) (PLGA) has demon-
strated optimal properties for the encapsulation of a large
variety of therapeutic agents and it is extensively employed in
nanomedicine.6,7 Moreover, PLGA-based nanocarriers have
been used as drug delivery systems to administer proteins,8,9
DNA10 and anticancer drugs among others.1,11,12 Nonetheless,
despite their compositional similarities, any novel PLGA-based
drug delivery system will require a thorough evaluation to
address potential toxicity issues and study the pharmacoki-
netics and the pharmacodynamics of each specific carrier.
Such preclinical in vitro and in vivo studies, comprising mul-
tiple biological characterization phases, could be expedited by
endowing the carrier with complementary imaging capacities.
For instance, in vitro cellular uptake can be easily imaged with
fluorescence13,14 while radioimaging15,16 or near infrared (NIR)
imaging1,17 are well suited for in vivo biodistribution studies.
However, the simultaneous incorporation of all these imaging
probes into a single nanocarrier unnecessarily increases the
complexity of the system, potentially limiting translation to the
clinics. Moreover, any additional component of the theranostic
carrier will have an enormous impact on the manufacturing
process, production cost and in complying with the medical
regulations. In this sense, a drug delivery nanocarrier easily
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adaptable to incorporate one or several imaging moieties in a
modular approach can be a smart strategy to guide the carrier
preclinical development while guaranteeing that a simpler
formula is used for the final product. However, this strategy is
suitable only when the inclusion or removal of the imaging
probes do not affect the size, shape and main compositional
traits of the final carrier.
Furthermore, conventional approaches to physically blend
imaging probes within the carrier can lead to incomplete con-
clusions or misinterpretations on the carrier’s
biodistribution.18,19 For example, loading two different mole-
cules as probes into the same carrier led to opposite con-
clusions regarding the kinetics of brain-specific delivery.19 A
growing body of evidence suggests that new methods will be
required to monitor nanocarriers’ biodistribution avoiding
interference of the imaging moieties with the encapsulated
drug or leaching of the imaging probes.19,20
Here, we report on PLGA nanocapsules (NCs) as a multi-
modal theranostic platform for in vivo drug delivery. We describe
the chemical synthetic routes to covalently label the PLGA with
biocompatible small molecule fluorophores or radioligands. It
involves the fabrication of PLGA NCs integrating several moieties
for their in vitro and in vivo imaging. Specifically, superpara-
magnetic iron oxide nanoparticles (SPIONs) enabled magnetic
resonance imaging (MRI), fluorescence imaging at different
emitting wavelengths (blue and NIR) and 89Zr-labeling enabled
positron emission tomography (PET) imaging. We show that the
morphology and size of PLGA NCs are not altered by either the
incorporation or the removal of one of the several imaging
probes. In all cases, the imaging moieties are chemically
attached to the PLGA shell matrix as opposed to being entrapped
in the core of the nanocapsule.13–15,17 This approach is advan-
tageous to avoid interferences of the imaging moieties with the
cargo in the core.21 This is especially important for delicate pay-
loads such as proteins, enzymes or microRNAs. For this, we have
used bovine serum albumin (BSA) as a model protein to evaluate
the protein loading capability.
Experimental section
All reagents were purchased from Sigma Aldrich unless other-
wise specified. The Ethics Committee of Animal
Experimentation of the Vall d’Hebron Research Institute
approved all experimental animal procedures (protocol
number 70.18), which were performed in accordance with the
Spanish legislation and the Directives of the European Union.
Experiments performed at CIC biomaGUNE were approved by
the Ethical Committee of the Institution and by the corres-
ponding authorities (Departamento de Promoción Económica,
Turismo y Medio Rural, Diputación Foral de Guipúzcoa;
project codes PRO-AE-SS-059 and PRO-AE-SS-067).
Modification and functionalization of the commercial PLGA
Synthesis of –NH2 terminated PLGA (PLGA-NH2). In order to
introduce a terminal amine group into PLGA, the carboxylic
acid terminal group of PLGA (lactic : glycolic ratio 50 : 50,
RG502H, Mw 12 000) was activated and reacted with ethylene-
diamine. The carboxylic groups were firstly activated with N,N′-
dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide
(NHS). 0.025 mmol of PLGA was dissolved in 8 ml of dichloro-
methane (DCM), and then 0.1 mmol of DCC in 1 mL of DCM
and 0.1 mmol of NHS in 0.5 mL of acetone were added into
the polymer solution under magnetic stirring. PLGA-NHS acti-
vation was achieved after 4 h at room temperature (RT). The
coupling reaction was accomplished by adding an excess
amount of ethylenediamine (0.15 mmol) in 1 mL of DCM to
the solution and further stirring for 2 h. The majority of the in-
soluble by-product, dicyclohexylurea, was removed by centrifu-
ging the solution after reaction at 9391 rcf for 15 min at 4 °C
and discarding the pellet. The supernatant was filtered
(0.2 µm PTFE syringe filter) to remove any trace of the in-
soluble by-product. PLGA-NH2 was precipitated by slowly
pouring the supernatant into an excess amount of ethanol
(10-fold), where the un-reacted NHS/DCC/ethylenediamine was
separated from PLGA-NH2 due to their solubility in ethanol.
Precipitated PLGA-NH2 was redissolved in DCM and reprecipi-
tated in ethanol twice for purification. The purified PLGA-NH2
was dried under vacuum.
Synthesis of fluorophore terminated PLGA using fluoresca-
mine (PLGA-fluram). Fluorescamine (fluram) is a non-fluo-
rescent compound that reacts with primary amines (R-NH2)
fast and near completely forming the fluorophore of fluram
derivative which emits strong fluorescence at λem = 465 nm (λex
= 390 nm).22 0.025 mmol of the as-synthesized PLGA-NH2 and
0.075 mmol of fluram were mixed and dissolved in 4 mL of
acetone and the reaction took place in a dark room after 2 h at
RT under magnetic stirring. Then the solution was slowly
dropped into an excess amount of ethanol (10-fold) to precipi-
tate the product PLGA-fluram. The PLGA-fluoram was collected
by centrifugation, redissolved in acetone and reprecipitated in
ethanol twice for purification. The purified PLGA-fluram was
dried under vacuum.
Synthesis of fluorophore terminated PLGA using Cy7.5
(PLGA-Cy7.5). NIR fluorophore cyanine7.5 (λem = 808 nm, λex =
788 nm) was introduced at the end of PLGA-NH2 by forming
an amide bond between the PLGA terminal amine group and
amine reactive Cy7.5 NHS ester (Lumiprobe GmbH, Hannover,
Germany). 0.025 mmol of the as-synthesized PLGA-NH2 and
0.05 mmol of Cy7.5 NHS ester were mixed and dissolved in
4 mL of acetone and 0.05 mmol of Et3N were added as the
catalyst. The reaction took place in the dark after 6 h at RT
under magnetic stirring. Then the solution was slowly poured
into an excess amount of ethanol (10-fold) to precipitate
PLGA-Cy7.5. The product was collected by centrifugation,
redissolved in acetone and precipitated in ethanol twice for
purification. The purified PLGA-Cy7.5 was dried under
vacuum.
Synthesis of DFO terminated PLGA (PLGA-DFO). 89Zr chela-
tor deferoxamine (DFO) was introduced at the terminal amine
of PLGA-NH2 by forming a thiocarbamide bond between the
PLGA terminal amine group and amine reactive p-NCS-Bz-DFO
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(CheMatech, Dijon, France). 0.025 mmol of the as-synthesized
PLGA-NH2 and 0.05 mmol of p-NCS-Bz-DFO ester were mixed
and dissolved in 4 mL of DMSO and 0.05 mmol of Et3N were
added as the catalyst. The reaction was accomplished after
12 h at RT under magnetic stirring. Then the DMSO solution
was mixed with 2-fold DCM and slowly dropped into 10-fold
diethyl ether to precipitate PLGA-DFO and unreacted
p-NCS-Bz-DFO, which were collected by centrifugation at 9391
rcf for 10 min. The PLGA-DFO/p-NCS-Bz-DFO mixture pellet
was dissolved in 1.5 mL of DCM and centrifuged at 13 171 rcf
for 60 min to remove the insoluble p-NCS-Bz-DFO. The super-
natant was further filtered (0.2 μm PTFE syringe filter) to
remove the traces of p-NCS-Bz-DFO. Finally PLGA-DFO was pre-
cipitated by slowly dropping the supernatant into 10-fold
diethyl ether, collected by centrifugation and dried under
vacuum.
Synthesis of SPIONs coated with oleic acid (OA-SPIONs)
SPIONs were synthesized through a microwave assisted
thermal decomposition in a microwave oven (Discover SP,
CEM Corporation) at a frequency of 2.45 GHz and 300 W of
power and then coated with oleic acid (OA).23 Briefly, the
process to obtain homogeneous OA-SPIONs with an average
diameter of 9 nm was as follows. In a microwave reaction glass
tube 3.5 mmol of iron precursor Fe(acac)3 was dissolved in
4.5 mL of benzyl alcohol. The tube was closed and microwave
irradiation occurred with the power set at 300 W. The solution
was kept at 60 °C for 5 min to fully dissolve the precursor and
subsequently heated to 210 °C and kept at this temperature for
30 min and then cooled down to room temperature. After the
reaction, a black colored dispersion formed which suggested
the formation of a magnetic material. Then 3.17 mmol of oleic
acid in 4 mL of toluene was added to the product dispersion
and sonicated for 1 h. Then 5-fold of acetone was added fol-
lowed by centrifugation to sediment the product pellet. The
pellet was redispersed in 4 mL of toluene and transferred into
a glass vial, a magnet was attached on the wall and after 5 s
the suspension containing SPIONs with smaller size and lower
magnetization was discarded. Then the pellet was redispersed
in 6 mL of DCM followed by centrifugation at 1075 rcf for
5 min to sediment the unstable big particles. The OA-SPIONs
of 9 nm stable in DCM were precipitated by adding 5-fold
acetone and centrifugation. The final black product was dried
under vacuum and redispersed in DCM at the concentration
required for use.
Fabrication of PLGA-based NCs and encapsulation of BSA
BSA encapsulated PLGA-based NCs were prepared by the
double emulsion solvent evaporation method. Briefly, 50 μL of
the inner aqueous phase (W1) containing BSA (30 mg mL
−1)
was emulsified in 500 μL of DCM organic phase (O) composed
of 50 mg of different proportions of PLGA/functional PLGA
and a certain amount of OA-SPIONs by sonication at 200 W for
28 s (VC505, Sonics & Materials, Inc., USA) to form the first
emulsion (W1/O). Then 2 ml of external aqueous phase (W2)
with PVA (20 mg mL−1) was added and the second emulsion
(W1/O/W2) was formed by sonication for an additional 28 s.
The temperature during the whole emulsion process was kept
at 4 °C by using an ice bath. The resulting double emulsion
was poured into 50 mL of MilliQ water and mechanically
stirred at RT for 2 h to allow complete evaporation of the
organic solvent and formation of NCs. Finally, the NC pellet
was obtained by centrifugation at 9391 rcf for 15 min and
washed three times with 50 mL of MilliQ water and then lyo-
philized in 6 mL of trehalose (2 mg mL−1) aqueous solution.
The as-obtained powder was stored at 4 °C with desiccant
silica gel.
Physicochemical characterization of the polymers, SPIONs and
PLGA-NC
ATR-FTIR, UV/Vis, TG, DLS. Attenuated total reflectance-
Fourier transform infrared (ATR-FTIR) characterization of the
polymers was performed on a Bruker Vertex 70 FTIR spectro-
meter with a Pike Miracle Single-Bounce diamond crystal plate
accessory at room temperature. FTIR spectra were recorded
over a wavelength range of 4000–500 cm−1 with a resolution of
4 cm−1. The ultraviolet-visible infrared (UV/Vis) spectra of the
fluorescent polymers were recorded on a Varian Cary-5000 UV/
Vis spectrophotometer using a quartz cuvette with an optical
path of 1 cm. Thermogravimetric (TG) analysis of oleic acid
coated SPIONs was carried out on a SETSYS Evolution TGA
(Setaram) from room temperature to 800 °C at a heating rate of
10 °C min−1 and under a dynamic dry air flow. Dynamic light
scattering (DLS) (Malvern Zetasizer) measurements of the
hydrodynamic diameter and size distribution of NCs by inten-
sity were performed by redispersing 0.5 mg of lyophilized
powder into 1 mL of MilliQ water.
Electron microscopies. A field emitting scanning electron
microscope (SEM, FEI Quanta 200 FEG) and a transmission
electron microscope (TEM, JEOL JEM-1210) were used to study
the morphologies of SPIONs and NCs. For the SEM sample
preparation of NCs, 0.5 mg of lyophilized powder was redis-
persed in 1 mL of MilliQ water and centrifuged at 4000 rpm
for 10 min. Then the supernatant was discarded to remove the
trehalose and 1 mL of fresh water was added, and the pellet of
NCs was redispersed in water with ultrasound. Finally, 6 μL of
the slightly turbid suspension was deposited onto a small slice
of silicon wafer stuck on top of a carbon layer and dried at
room temperature overnight. The sample was sputtered with
Au–Pd (Emitech K550 Sputter Coater, 20 mA for 2 min). TEM
samples were prepared by placing and drying one drop of the
corresponding NC or SPION dispersion on a copper grid at
room temperature.
SQUID. Superconductive quantum interference device
(SQUID, Quantum Design MPMS5XL) was used to measure the
magnetization of NCs and SPIONs and calculate the experi-
mental SPION loading (wt%SPIONs) and EE%SPIONs of NCs. A
gelatin capsule filled with about 7 mg of samples topped with
some cotton wool was inserted into the SQUID magnetometer
sample holder and the hysteresis loop was measured from −50
kOe to 50 kOe at 5 K. The remnant magnetization of the mag-
netic NCs (MR, NCs, emu g
−1) and of SPIONs (MR, SPIONs, emu
Paper Nanoscale
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g−1) at 5 K was used to calculate wt%SPIONs and EE%SPIONs as
follows:
wt%SPIONs ¼ MR;NCsMR; SPIONs  100%
EE%SPIONs ¼ Experimental SPION loadingNominal SPION loading  100%
Fluorescence properties. Fluorescence spectra of the
polymer PLGA-fluram were acquired on a PerkinElmer LS45
spectrofluorometer. Both the excitation and emission-slit
widths were set at 10 nm. The quantum yield of the polymer
was measured by the Williams’ method24 shown in Fig. S3a.†
The molar extinction coefficient (ε, mol−1 L cm−1) of PLGA-
fluram was calculated according to the Beer–Lambert law, A =
εCL. Here C and L are the concentration (mol L−1) and length
(cm) of the dye solution in a UV/Vis cuvette respectively.
Brightness and photostability are two important intrinsic
photophysical properties of fluorescent materials. The bright-
ness intensity of PLGA-fluram can be calculated by the extinc-
tion coefficient multiplied by the quantum yield.
Photostability was measured by continuously illuminating
polymer solution with excitation light at 390 nm and measur-
ing the resulting emission at 483 nm for 3 h. The photostabil-
ity of rhodamine B as a reference was tested with its maximum
excitation at 540 nm and maximum emission at 625 nm for
the same 3 h in aqueous solution. Fluorescence signals of
different concentrations of PLGA-fluram NC in saline were
quantified in a 96-well plate by a microplate reader. The NCs
were excited at the maximal excitation wavelength and the
fluorescence signal was collected at the maximal emission
wavelength.
In vitro and in vivo MRI of the NC·SPIONs
In vitro agarose phantoms of NCs were prepared by filling a
series of glass microtubes with solutions of 0.63% agarose in
water (Conda, Madrid), into which different amounts of NCs
were admixed. The corresponding iron doses (mmol L−1) were
calculated according to the wt% of SPIONs in each sample. T2
weighted images (T2WI) of the phantoms were acquired at 7 T
in a 70/30 Bruker USR Biospec system (Bruker GmbH,
Ettlingen) as follows: multi-slice multi-echo (MSME) sequence
with echo time (TE) = 8 ms, repetition time (TR) = 2600 ms,
average N = 2, matrix size = 160 × 160, field of view (FOV) = 24
× 24 mm, 14 slices of 1 mm thickness, and spectrometer band-
width (BW) of 474 Hz per pixel. Quantitative T2 values were
obtained from hand-drawn regions of interest (ROIs) by using
curve fitting in the Image Sequence Analysis (ISA) Tool
(ParaVision v.5.1).
Balb/c female mice (16–17 weeks of age, n = 2) were
anesthetized with isoflurane (IsoFlo; Abbott Laboratories).
T2WI were acquired pre- and 15–20 min post-administration of
NCs (1.6 mg in 150 μL of saline through tail vein) using the fol-
lowing imaging parameters: MSME pulse sequence, 20 echo
times with ΔTE = 8 ms, TR = 2.6 s, N = 2 averages, a matrix of
256 × 256 points covering a FOV of 25.6 × 25.6 mm2, giving a
resolution of 100 µm in plane, 14 continuous slices of 1 mm
thickness, and BW = 75 kHz. The images were acquired with a
respiratory gating by using a SAII Model 1030 monitoring &
gating system (Smal Animals Instruments, Stony Brook, NY,
USA). Fat suppression was achieved by a saturation pulse of
1050 Hz. T2 maps were constructed off-line using Image-J
1.50b (National Institutes of Health), and data were fitted to a
three parameter exponential decay equation (S = A + S0 exp
(−TE/T2), where S represents signal intensity, A, S0 and T2 are
the fitting parameters), achieved by the “exponential decay
with offset” equation of the fitting routine of ImageJ. Signal
intensities in T2WI and T2 maps were quantified manually in
selected ROIs using ImageJ. Afterwards mice were euthanized
and organs were preserved for histological analyses.
In vitro and in vivo NIRF imaging of NC·PLGA-Cy7.5
A series of concentrations of NCs in 100 μL of saline (n = 3)
were prepared in a 96-well plate and imaged using a Xenogen
IVIS® spectrum (λex/λem 710/820 nm). BALB/cAnNRj male mice
(Janvier; 7–8 weeks of age, n = 2) were deeply anesthetized with
isoflurane and were injected via the tail vein with NCs at a
dose of 1.6 mg in 200 μL of saline. The NIRF images were
acquired on a Xenogen IVIS® spectrum imaging system at
0.5 h, 1 h and 3 h post injection. At the end of the 3 h scan,
the mice were euthanized to image the signal intensity of the
principal organs ex vivo together with blood and urine.
In vivo PET imaging of 89Zr labelled NC·PLGA-DFO
NC·PLGA-DFO were labelled with 89Zr as follows: [89Zr]ZrC2O4
was produced in house following a standard protocol. The as-
obtained 1500 µL of 1 M oxalic acid containing 89Zr (8.2 mCi,
303.4 MBq) were neutralized with 2 M sodium carbonate (pH
= 7.2) and the volume was adjusted to 3.5 mL with 0.5 M
HEPES buffer. Six aliquots (1.6 mg each) of the lyophilized par-
ticles were dispersed in 50 µL MQ-water, and 450 µL of the
freshly prepared 89Zr-solution was added to each and mixed
well by sonication. After incubating overnight at room temp-
erature the particles were purified by centrifugation and
washed two times with MQ-water followed by one wash with
saline to remove all non-bound 89Zr. The pellet of the last
wash was dispersed in 120 µL of saline with an average calcu-
lated radiochemical yield of 70.1% (decay-corrected). As the
achieved samples were too high in activity, a one to one
dilution with non-labelled particles was performed. The final
injections (150 µL) were performed intravenously via the tail
vein of healthy female mice (Crl : CD1(ICR)) with an average
injected activity of 161 µCi (6.0 MBq).
Imaging studies were conducted using positron emission
tomography (PET) in combination with computerized tom-
ography (CT), using the β- and X-cube microsystem of
Molecubes. Static whole body images (1 bed) were acquired in
a 511 keV ± 30% energetic window at 1 h, 4 h, 23 h and 47 h
post injection (acquisition time 5 min for 1 h and 4 h, 20 min
for 23 h and 47 h). PET images were analyzed using PMOD
image analysis software (PMOD Technologies Ltd, Zurich,
Switzerland).
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Prussian blue stain
Liver samples from the mice subjected to PET were embedded
in an optimal cutting temperature (OCT) compound and kept
at −80 °C until sliced in 8 µm sections with a cryostat. After
rehydration, the sections were stained with a Prussian blue
iron stain kit (Polysciences Inc, USA) following the manufac-
turer’s protocol except that potassium ferrocyanide :
hydrochloric acid solution was kept for a total of 40 minutes
and nuclear Fast Red for 1 minute. Images were acquired after
dehydration with a transmitted light microscope (Leica,
Germany).
In vitro and in vivo toxicity evaluation of the NCs
Cell viability evaluation. The toxicity of the NCs on human
brain endothelial cells (hCMEC/D3) and CD34+ endothelial
cells25,26 was assessed by performing a viability assay with 3-(4-
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT). For the hCMEC/D3 cells, 2 × 104 viable cells were dis-
tributed on a 24-well plate in 400 μL Endothelial Growth
Media (EGM2 from Lonza with 2% fetal bovine serum and half
the amount of the growth factors included in the kit) whereas
5 × 103 viable CD34+ endothelial cells were seeded on a 96-well
plate in complete media. Both cell types were incubated for
24 h at 37 °C and 5% of CO2. After this period, culture super-
natants were substituted with basal cell culture media (serum-
free medium) containing increasing doses of NCs at concen-
trations of 25 μg mL−1, 50 μg mL−1, and 100 μg mL−1 (N = 3,
triplicate). The MTT assay was performed after 48 h of incu-
bation, and the absorbance of the resulting formazan crystals
diluted in DMSO was determined at 540 nm. Cell viability was
referred to as the percentage of viability compared with the
control conditions (without NC).
In vivo safety. Body weights of mice were monitored period-
ically at 0 d, 1 d, 5 d, 8 d, 11 d and 13 d after i.v. injection of
NCs in 150 µL of saline at a dose of 0.84 mg Fe per kg (n = 5),
where the vehicle group received 150 µL of saline (n = 5) and
the naïve group without treatment served as control (n = 3). At
the end of 13 days blood samples were collected and liver/pan-
creas toxicity based on specific enzyme levels in plasma was
analysed in all groups: alanine aminotransferase (ALT), alka-
line phosphatase (ALK), aspartate aminotransferase (AST) and
α-amylase using an Olympus AU5800 clinical chemistry
analyser.
BSA loading content
The albumin content was determined directly using the
CBQCA protein assay kit (Invitrogen™ ref. C6667), which
determines the protein concentration based on the production
of fluorescent products measurable at λex/λem = 450 nm/
550 nm via non-covalent interaction between CBQCA and
primary aliphatic amines of proteins. This highly sensitive
fluorescence-based method showed compatibility with DMSO,
SPIONs, detergents and other substances which interfere with
many commonly used protein determination methods.
Lyophilized NCs encapsulating albumin as well as empty NCs
as control were fully dissolved in DMSO at 100 mg mL−1. The
protein contents in the NC lysates were measured and calcu-
lated based on the difference in fluorescence with control and
a calibration curve drawn with standard albumin solutions,
and the protein contents in the BSA solutions used for encap-
sulation were also measured. All determinations were per-
formed in duplicate for each NC batch. The experimental BSA
loading content was expressed as μg of BSA per mg of NCs (μg
mg−1). The encapsulation efficiency (EE%) was calculated as
follows:
EE%BSA ¼ Experimental BSA loading
Nominal BSA loading
 100%
Results and discussion
PLGA NCs reported here incorporate several biocompatible
multimodal imaging modalities (Fig. 1): fluram and cyanine
7.5 (Cy7.5) as fluorescent probes in the blue and the near-
infrared (NIR) wavelengths, 89Zr chelated with DFO as a radio
imaging probe and SPIONs as a MRI contrast agent. The fluo-
rescent probes and the DFO chelator were anchored to an ami-
nated PLGA, PLGA-NH2, resulting from the modification of the
commercial carboxylic acid-terminated PLGA. BSA encapsu-
lated PLGA NCs could then be prepared by a double emulsion
solvent evaporation method where selected imaging moieties
were incorporated into the PLGA shell by adding the desired
Fig. 1 Schematic illustration of a PLGA NC as a tailor-made multimodal theranostic platform.
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proportions of a given functional PLGA and oleic acid coated
SPIONs to the organic phase while the BSA was added to the
aqueous phase.
Chemical modification of the PLGA with functional moieties
Fig. 2 shows the schematic representation for terminal modifi-
cations and functionalization of the PLGA. Firstly, the car-
boxylic acid end group of PLGA was activated with DCC and
NHS to conjugate ethylenediamine and form PLGA-NH2,
bearing a free primary amine group in the PLGA end (Fig. 2a).
An excess amount of ethylenediamine (6 : 1
ethylenediamine : PLGA mole ratio) was used to suppress the
coupling reaction of PLGA–PLGA that could occur due to the
homo-functional crosslinker ethylenediamine. Subsequently,
the three functional moieties with amine-reactive groups
(fluram, Cy7.5, DFO) could be respectively integrated at the
end of the PLGA molecule through coupling reactions
(Fig. 2b). Further details are reported in the Experimental
section.
ATR-FTIR spectra of the commercial PLGA-COOH and the
PLGA-NH2 product confirmed their similar chemical structure
and successful modification (Fig. S1 in the ESI†). The reaction
efficiency of PLGA-COOH to PLGA-NH2 was quantified by
measuring the conjugated amount of fluram to the –NH2
groups. The UV absorbance of the PLGA-NH2 product (Mw
12 000 g mol−1) in chloroform at 390 nm due to the conju-
gation of fluram was compared with a standard calibration
curve constructed from different concentrations of ethylene-
diamine prepared under the same conditions (Fig. S2†). A reac-
tion efficiency of 86% of PLGA-COOH to PLGA-NH2 was esti-
mated, which means that the molar fraction of pure PLGA-NH2
in the product was 0.86.
Fluram is a non-fluorescent compound that reacts quickly
and almost quantitatively with primary amines (R-NH2) to
form a fluorescent derivative, which emits strong fluorescence
at around 480 nm when excited at 390 nm.22 The conjugation
of this compound to the –NH2 end of PLGA for fluorescence
application is very advantageous considering that neither free
fluram itself nor its hydrolysis product show fluorescence. As
shown in Fig. 3a, the characteristic absorption peak of the
fluorophore at 390 nm occurred in the UV-Vis spectrum of the
conjugation product PLGA-fluram but this was not observed
either in PLGA-NH2 or in fluram. The disappearance of the
309 nm absorption band of fluram in the PLGA-fluram
product indicates that the purification process removes the
vast majority of free fluram. The fluorescence of the obtained
PLGA-fluram was evaluated and the excitation and emission
spectra are depicted in Fig. 3b. Importantly, the fluorescence
intensity of PLGA-fluram decreased only slightly (<5%) after
continuous UV excitation at the maximum excitation wave-
Fig. 2 PLGA chemical modifications. Synthetic schemes of terminal modifications and functionalization of the PLGA.
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length for 3 h, thus exhibiting a photostability just slightly
lower (2%) than rhodamine-B, a widely used commercial fluo-
rescent dye (Fig. 3c). The photostability of PLGA-fluram using
a confocal microscope configuration is also included in
Fig. S3b.† The fluorescence intensity of NCs fabricated by
PLGA-fluram decreased by only 13% after 10 min of continu-
ous illumination at 10% of laser power (401 nW). Considering
that the laser power applied to observe stained cells is gener-
ally less than 10%, our fluorescent NCs would exhibit good
photostability under in vitro conditions. Note that the calcu-
lated quantum yield of PLGA-fluram (18%) (Fig. S3a†) is much
higher than the values reported for fluorescent proteins such
as green fluorescent protein (GFP) (7.3%) and its blue variants
(7.9%),27 and similar to other polymeric fluorescent materials
such as poly(amido amine)s.28,29 Finally, the calculated fluo-
rescent brightness of PLGA-fluram (25056) is also much higher
than that of other reported biodegradable photo-luminescent
poly(lactide-co-glycolide) (BPLP-co-PLGA) (6550–19230)30 and
other frequently used small organic dyes such as Alexa Fluor
430 (8800) or DAPI (15660). The fluorescence intensities of the
fabricated NCs show linear dependency on the NC concen-
tration, and NCs can be clearly imaged with a fluorescence
microscope (Fig. 3d). Although in this work we have focused
on in vivo imaging modalities, the remarkable fluorescence
properties shown here endow the PLGA-fluram system with
very interesting features for in vitro fluorescence tracking
studies.
Next, the NIR fluorophore Cy7.5 was introduced into the
terminal amine of PLGA-NH2 via an amide bond between the
PLGA terminal amine group and amine-reactive Cy7.5 NHS
ester. The absorption band of Cy7.5 appeared in the UV-Vis
spectrum of the PLGA-Cy7.5 product, which confirmed the
successful conjugation of Cy7.5 (Fig. S4a†). The amount of
conjugated Cy7.5 in the PLGA-Cy7.5 product was quantified by
comparing the fluorescence intensity of the PLGA-Cy7.5
product with freeCy7.5 (Fig. S4b†) in DMSO. Pure PLGA-Cy7.5
with a molar fraction of 0.65 was estimated in the product and
a conjugation efficiency of 76% of the Cy7.5 NHS ester to
PLGA-NH2 was calculated considering that the fraction of pure
PLGA-NH2 is 0.86.
For radiolabelling functionalization the 89Zr chelator DFO
was introduced at the end of PLGA-NH2 by forming a thiocar-
bamide bond between the PLGA terminal amine group and
the amine reactive –NCS group in the DFO derivative
Fig. 3 PLGA-fluram system spectroscopic and fluorescence characterization. (a) UV-Vis absorption spectra of PLGA and PLGA/fluram samples; (b)
excitation and emission spectra of PLGA-fluram; (c) photostability evaluation of PLGA-fluram and control dye rhodamine B, fluorescence intensity
expressed as the percentage vs. time 0; (d) fluorescence intensity of different concentrations of NC·PLGA-fluram (NC-4) vs. NC-control (NC-3)
measured by using a microplate reader (n = 3, values represent mean ± SEM); insert: lyophilized NC-4 observed under a fluorescence microscope
with DAPI/GFP filters, scale bar 60 μm.
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p-NCS-Bz-DFO. Compared to the IR spectrum of PLGA-NH2,
some new bands corresponding to the DFO conjugate appear
in the spectrum of PLGA-DFO, indicating the successful conju-
gation of DFO (Fig. S1†). The amount of conjugated DFO in
the PLGA-DFO product was quantified by measuring the
amount of unreacted PLGA-NH2 through the fluram method
described above (Fig. S2c†). Pure PLGA-DFO with a molar frac-
tion of 0.75 was estimated in the product, and a conjugation
efficiency of 88% of p-NCS-Bz-DFO to PLGA-NH2 was calcu-
lated considering that the fraction of pure PLGA-NH2 is 0.86.
Fabrication of PLGA NCs with selected combinations of
imaging moieties
PLGA NCs with encapsulated BSA were prepared by a double
emulsion solvent evaporation method.31 Imaging moieties
were incorporated into the PLGA shell by adding to the
organic phase various proportions of functionalized PLGA as
well as the oleic acid (OA) coated SPIONs (Table 1).
Compositional changes of the organic phase did not affect the
encapsulation process, and all types of NCs prepared showed
mean hydrodynamic sizes within a diameter range of
250–300 nm and a polydispersity index (PdI) <0.2. As seen in
Table 1 from NC-1 to NC-3, neither increasing the SPION size
nor increasing two-fold its loading affected the mean size of
the NCs compared to plain PLGA NCs (NC-0). Note that for the
same loading of SPIONs, the magnetization of NC-2 is much
higher than that of NC-1 given the larger size of SPIONs for
NC-2. Therefore optimal formulation regarding SPIONs
(6 wt%, with 9 nm nanoparticles) yields an average saturation
magnetization value of 4.06 emu g−1 NCs which is more than
four-fold larger than our previously reported value (0.90 emu
g−1).31 As will be shown later, the increase of the magnetic
moment of NCs resulting from using larger size SPIONs and
increasing their load will positively impact on the MRI signal
intensity.32
Furthermore, the size of NCs as well as the encapsulation
efficiency (EE%) of SPIONs were not affected when various pro-
portions of PLGA-fluram (NC-4), PLGA-DFO (NC-5) or
PLGA-Cy7.5 (NC-6) were incorporated into the PLGA matrix,
even when incorporating various moieties simultaneously
(NC-7). Importantly, we had found that the PLGA-based NCs
can be fabricated using either up to 100 wt% of any modified
PLGA (PLGA-DFO, PLGA-Cy7.5 or PLGA-fluram) or with any
mixed proportion of them without affecting the morphology of
NCs and EE% of SPIONs. This can be explained by the
forming process of the NCs: the different functional moieties
at the end of the comparatively extra-long PLGA molecules do
not affect the film-forming of PLGA and the entrapment of
SPIONs in the polymeric matrix. Finally, PEGylation of the
PLGA NCs was achieved by adding a given amount of the com-
mercial amphiphilic block copolymer PLGA-PEG (PEG Mn 5000
and PLGA Mn 7000) to the organic phase. The morphology and
size of NCs (NC-8) are maintained up to a maximal fraction of
7 wt% amphiphilic PLGA-PEG (3 wt% PEG, Table 1) and are
not affected when co-incorporating other hydrophobic modi-
fied PLGA (i.e., PLGA-Fluram/PLGA-DFO/PLGA-Cy7.5) (data not
shown).
Fig. 4 shows a representative scanning electron microscopy
(SEM) image of the NCs (NC-3) presenting homogeneous
spherical morphologies. The inset is a dynamic light scattering
(DLS) size distribution histogram of lyophilized NCs redis-
persed in water. In this case, the mean hydrodynamic dia-
meter of the NCs is 276 nm with a polydispersity index (PdI) of
0.18 reflecting good redispersibility of the NCs in water after
the lyophilization process. As mentioned, all types of NCs
listed in Table 1 had similar morphologies and sizes (Fig. S7†),
which were considered to be suitable for intravenous adminis-
tration.33 The upper inset in Fig. 4 shows a representative
broken NC, exposing the hollow core, ideal for the loading of
protein drugs. The transmission electron microscopy (TEM)
Table 1 Summary of the formulations of PLGA-based NCs. Different proportions of modified PLGA and SPIONs were mixed in the organic phase
during the double emulsion process
Sample
type
PLGA information (wt%) SPIONs
MR
(emu g−1)
MS
(emu g−1)
Size (DLS)
PLGA PLGA-Fluram PLGA-DFO PLGA-Cy7.5 PLGA-PEG
Sizea
(nm)
Loadingb
(wt%) EE%b d.nm PdI
NC-0 100 — — — — — — — — — 255 0.10
NC-1 100 — — — — 6 2.9 92% 0.4 1.0 279 0.17
NC-2 100 — — — — 9 3.0 90% 0.8 1.9 264 0.19
NC-3 100 — — — — 9 6.1 95% 1.6 3.9 276 0.18
NC-4 50 50 — — — 9 6.2 95% 1.6 4.7 260 0.15
NC-5 40 — 60 — — 9 6.3 97% 1.6 4.3 271 0.19
NC-6 40 — — 60 — 9 5.9 91% 1.5 3.6 245 0.11
NC-7 — 50 50 — — 9 5.9 91% 1.5 3.7 268 0.18
NC-8 93 — — — 7 9 6.0 92% 1.6 3.8 265 0.13
OA-SPIONsc 6 14.0 50.8
9 26.1 75.1
a The size of SPIONs was determined by statistics from TEM images (Fig. S5†). b SPION loading and entrapment efficiency (EE%) were determined
by SQUID measurements at 5 K. c The fraction of SPIONs in OA-SPIONs was determined by thermogravimetric analysis (TGA) and the magnetiza-
tion is expressed as emu g−1 SPIONs (Fig. S6†).
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image in the lower inset revealed the embedding and finely
homogeneous distribution of the SPIONs within the polymeric
matrix.
NC magnetic properties, accumulation and biodistribution by
MRI
The magnetic hysteresis loop at room temperature of lyophi-
lized NC-3 is displayed in Fig. 5a showing the superpara-
magnetic character of the NCs (lack of coercivity). The super-
paramagnetic behavior of the NCs after SPION encapsulation
is important since in the absence of an external magnetic
field, it ensures lack of interactions among NCs thus minimiz-
ing the risk of embolization for i.v. administration. The mag-
netic retention of NCs is illustrated with the use of an external
magnet. As seen in Fig. 5b, the colloidal water suspension of
2 mg mL−1 of NC-3 forms a round pellet next to the magnet
after 7 h. The solution becomes completely clear indicating
that a great majority of the NCs are retained by the magnet.
Previous experiments using magnetic PLGA nanoparticles34 or
microparticles loaded with only 1 wt% iron oxide35 already
demonstrated magnetic retention in rodent brain or knees,
indicating that our protein loaded magnetic NCs with a higher
magnetic load (6 wt%, MS = 4 emu g
−1) may still have better
characteristics to address magnetic targeting.
Fig. 4 Morphological data of a representative PLGA NC system (NC-3).
SEM image of lyophilized PLGA based NCs with the upper inset showing
the hollow core of the NC; lower inset TEM image shows a spherical NC
with SPIONs visible as black spots, uniformly distributed in the polymer
matrix; DLS curve of NC water suspension after lyophilization with a
mean diameter of 276 nm and 0.18 polydispersity.
Fig. 5 Magnetic characterization, retention and MRI phantoms of PLGA–SPIONs NCs. (a) Hysteresis loop of the lyophilized batch NC-3 at 300 K,
showing superparamagnetism at room temperature; (b) glass tube with water suspension of NC-3 at a concentration of 2 mg mL−1. A permanent
magnet (diameter 8 mm, surface field ∼0.4 T) was placed on the wall. After 7 h, the NCs adsorbed to the tube wall on the magnet side; (c) T2-
weighted phantoms obtained by mixing lyophilized NCs with agarose at increasing NC concentrations, on the left are TEM images of NCs; (d) evalu-
ation of r2 relaxivities for NC-3 and NC-2 (3 wt% and 6 wt%; 9 nm diameter).
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Phantom studies were conducted to confirm the MRI per-
formance of the NCs. Phantoms from two batches (NC-2 and
NC-3) with different SPION loadings (3 wt% and 6 wt%; 9 nm
diameter) at a series of concentrations were prepared (Fig. 5c).
Spin–spin relaxation time (T2) weighted color-coded MRI
images clearly exhibit signal decay in a concentration depen-
dent manner. Importantly, at the same concentration NC-3
with 6 wt% SPIONs showed a higher T2 signal decay rate than
NC-2 with 3 wt% SPIONs indicating that NC-3 will be easier to
track in vivo by MRI. Furthermore, the transverse relaxivity (r2)
value at 7 Tesla of NC-3 (336 mM−1 s−1) was higher, as
expected, than that of NC-2 (278 mM−1 s−1) as seen in Fig. 5d,
indicating that the denser packing of SPIONs in a single NC of
NC-3 endows the NCs with a larger magnetic moment and
increases its efficiency as a spin–spin relaxation agent.36
Compared with other clinically used SPION systems such as
Feridex (98 mM−1 s−1) and Resovist (151 mM−1 s−1),37 the
much higher r2 value in our final NC formula (6 wt% SPIONs
of 9 nm in diameter) is expected to be useful for in vivo MRI
tracking of the NCs.
As the representative abdominal images show in Fig. 6b, a
much clearer increase of the contrast of the liver was observed
in both T2WI and T2 maps after NC administration, illustrat-
ing the fast accumulation of NCs in the liver. Quantitative ROI
analysis in Fig. 6c shows a 55% drop of signal intensity (SI) on
T2W images and a 26% drop of T2 relaxation time in the liver,
while a negligible signal drop was observed in the kidney,
which further demonstrate the large accumulation of NCs in
this organ. To further confirm the presence of NCs in the
tissue, Prussian blue staining on liver sections confirmed the
presence of ferric iron (Fig. 6d) after the in vivo MRI.
Biodistribution of the NCs monitored by PET
With a ∼3 day half-life, 89Zr-based PET imaging holds great
potential as a useful tool for long-term monitoring of the
dynamic biodistribution, biodegradation and clearance
pathway of nanoparticles in vivo.38 Our results showed that
89Zr-labelling has a yield of about 70% for NC·PLGA-DFO
(NC-5) after overnight incubation at room temperature at a
concentration of 3 mg mL−1. A DFO challenge study has been
Fig. 6 In vivo mouse MRI of the PLGA–SPIONs NCs and liver Prussian blue iron-stain. (a) Representation of the abdominal region with organ posi-
tioning and ROI quantification in the kidney and liver (1: liver, 2: kidney cortex, 3: kidney medulla, 4: paravertebral muscle used for normalization). (b)
Representative images of T2W and T2 maps before and after NC-3 administration. (c) Signal intensity (SI) and relaxation time (ms) were calculated
for each ROI corresponding to the analyzed anatomical structures which were then corrected by muscle ROI SI. Final data are represented as post-
administration SI or T2 relaxation as the percentage of the pre-administration values (mean ± SEM; n = 2). (d) Representative images of Prussian blue
stain for ferric iron in liver sections of naïve and treated animals administered with NC-3 in the MRI study (blue spots).
Nanoscale Paper
This journal is © The Royal Society of Chemistry 2020 Nanoscale, 2020, 12, 4988–5002 | 4997
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
Ja
nu
ar
y 
20
20
. D
ow
nl
oa
de
d 
on
 5
/2
5/
20
20
 3
:5
8:
12
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
reported to demonstrate the radiostability of 89Zr-labelled
nanoparticles.39 In our study, the as-obtained
NC·PLGA-DFO-89Zr was suspended in 1 mM DFO aqueous
solution and incubated at 37 °C for 23 h. Then the NCs were
separated by centrifugation and 100% were still labelled, with
no presence of 89Zr-DFO in the supernatant, demonstrating a
strong binding affinity of 89Zr to the NC·PLGA-DFO.
89Zr labelled NC·PLGA-SPIONs-DFO-89Zr (NC-5) were then
injected via the tail vein with the same iron dosage as for the
MRI study (1.68 mg Fe per kg−) to anesthetized mice. Static
whole body PET-CT images were acquired at 1 h, 4 h, 23 h and
47 h p.i. Dominant liver, spleen and lung uptake was observed
(Fig. 7a) and confirmed by the quantitative ROI analysis
(Fig. 7b) within two days, which can be related to phagocytic
cell uptake by the mononuclear phagocyte system,1 as expected
for i.v. injected PLGA nanoparticles of this size.17 Interestingly,
noticeable bladder accumulation (∼22%ID cm−3) was observed
at 1 h p.i., with a sharp decrease at 4 h p.i. (∼6%ID cm−3)
likely due to uncontrolled animals’ urination between scans.
The early stage activity in the bladder could also be confirmed
by continuous PET-CT acquisition (Fig. S8†), which showed a
linear increase of activity within 3 h p.i. It is hard to assign the
activity in the urine to the detachment of free 89Zr from the
NCs, since detached free 89Zr is a well-known osteophilic
cation with a fast and retained uptake in bones,38,40 which is
not detectable in our case. In the study of Chen et al.,38 for
both free 89Zr-oxalate or 89Zr labelled SiO2 nanoparticles, fast
and sustained uptake of free/detached 89Zr in bones and joints
was observed from the first few hours up to three weeks, while
the accumulation in the bladder was negligible. We thus
hypothesized that the erosion of the soft polymeric NCs had
happened at an early stage in the complex blood circulation
environment. The detached 89Zr-molecular fragments from the
NCs, either by degradation of ester bonds in PLGA molecular
chains or thiocarbamide bonds between PLGA and DFO or by
mechanical force, with a size smaller than 15 nm (ref. 41)
underwent renal clearance and were observed in the bladder.
Additional experiments showed erosion of NCs clearly
observed after in vitro incubation in mouse plasma at 37 °C for
24 h (Fig. 7c). Small holes appeared on the NCs while under
the same conditions NCs incubated in saline did not show the
same eroded surface (Fig. 7d). Considering the in vivo blood
Fig. 7 PET biodistribution study of PLGA-SPIONs-DFO-89Zr NCs. (a) Representative PET-CT coronal images of mice obtained at different time
points after intravenous (i.v.) administration of NC·PLGA-SPIONs-DFO-89Zr (NC-5). PET images (maximum intensity projections) have been co-regis-
tered with CT images (slices) of the same animals for localization of the radioactive signal; (b) accumulation of radioactivity, expressed as a percen-
tage of injected dose per cm3 of tissue (%ID cm−3) at 1 h, 4 h, 23 h and 47 h p.i. (mean ± SEM of n = 2); (c) and (d) SEM images of the NCs after incu-
bation for 24 h at 37 °C in mouse plasma or saline.
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circulation setting, the erosion of PLGA NCs would be much
faster as reported by Swider.42 Not surprisingly, at late time
points the concentration of radioactivity in the bladder
decreases likely due to the fast accumulation of the NCs in the
liver/spleen.
NC biodistribution monitored by near infrared fluorescence
(NIRF) imaging
To investigate the feasibility of the formulation of
NC·PLGA-Cy7.5 (NC-6) for in vivo NIRF imaging, in vitro fluo-
rescence performance was firstly checked. The in vitro fluo-
rescence intensity of NC-6 was linearly dependent on the con-
centrations of NCs, showing strong fluorescence and no
quenching up to a high level of 1 mg mL−1 (Fig. 8a). Real-time
whole-body imaging revealed a dominant abdominal distri-
bution of the NCs with a total radiant efficiency (TRE) of
∼42.40 vs. control at 2 h p.i. At the end of the observation,
main organs including brain, heart, lungs, liver, spleen,
kidneys, and bladder were collected. Fig. 8c shows a represen-
tative ex vivo fluorescence picture of those organs and Fig. 8d
shows the quantified result of the biodistribution of the NCs.
Dominant liver, spleen and lung accumulation was observed
which was consistent with the data acquired with PET. Note
that we also did see the bladder signal during the real-time
imaging, which further demonstrated that the erosion of NCs
really occurred at the early stage p.i., considering that the
NIRF imaging is less sensitive than PET. The unobservable
ex vivo bladder signal may result from the uncontrolled urina-
tion and urine sample collection.
From the above discussion, similar biodistribution of the
NCs with different imaging probes for MRI/PET/NIRF was evi-
denced. That was expected since the only difference among
the NCs for these three imaging modalities is the existence or
not of small molecule 89Zr-DFO or Cy7.5 at the end of the
PLGA molecular chain. As we have demonstrated, the imaging
probes in the matrix of the PLGA shell do not affect the size of
the NCs, which is a key attribute influencing the biodistribu-
tion and pharmacokinetics of the nanocarriers.17,41,43 Thus,
the incorporation or removal of these small molecules in the
shell does not affect the NCs’ in vivo biodistribution and
tailor-made capsules can be fabricated with the appropriate
imaging probe needed for each specific in vivo and in vitro
Fig. 8 Fluorescence molecular imaging of PLGA-SPIONs-Cy7.5 NCs. A Xenogen IVIS® imaging system (λex/λem 710/820 nm) was used to monitor
the NIRF signal of NC-6, and the fluorescence intensity was quantified as total radiant efficiency (TRE) vs. the corresponding control. (a) Quantitative
in vitro NIRF intensity of different concentrations of NCs vs. control saline (n = 3, mean ± SEM) and representative images of NCs in the well; (b)
representative whole body in vivo images obtained at different time points after i.v. injection; (c) representative ex vivo images of excised organs at
the end of the in vivo experiment; (d) ex vivo quantification of biodistribution of NCs determined by the averaged organ TRE vs. the control mouse (n
= 2, mean ± SEM).
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study. Moreover, simultaneous multimodal imaging is an
option through custom-tuning the functional moieties in the
capsules. Despite that bare (non-PEGylated) NCs were used
here, the PLGA NCs can also be easily pegylated as shown for
the NC-8 system (3 wt% PEG Mn 5000) and modify the blood
circulation time of NCs. Moreover, the magnetic functionality
could be exploited for magnetic targeting in a selected organ
or tissue.
In vitro and in vivo safety studies of NCs
In vitro and in vivo safety studies of NC-3 (PLGA-SPIONs NCs)
were conducted considering that this is the simplest thera-
peutic formulation for magnetically targeted delivery. We
tested the effect of NC-3 on the proliferation/viability of
human endothelial cells since endothelial cells lining the
blood vessels are the first NC target following their intravenous
administration. Thus, human brain endothelial cells (hCMEC/
D3), a cell line derived from brain microcirculation, and
primary cultures of human CD34+-derived endothelial cells
were exposed to NC-3 and its cytotoxicity was evaluated by per-
forming a MTT assay. As shown in Fig. 9a, the cells did not
exhibit a decrease in viability after being exposed for 48 h to
the NCs from 25 to 100 μg mL−1, and the differences in cell
viability between groups were not significant (ANOVA >0.05),
thus our results suggest that the NCs are biocompatible for the
studied range of concentrations and time. Thereafter, the sys-
temic effect of NCs via i.v. administration was evaluated.
Fig. 9b shows that after injection of NCs, all animals main-
tained the body weight within normal values for two weeks (no
differences between groups at the end of the experimental
period), with no significant morbidity and no potential
adverse effects. At the same time, blood sample tests to
monitor potential liver and pancreatic toxicity showed that
none of the biomarker enzymes were significantly different
between groups and similar to those measured in non-treated
mice (Fig. 9c; ANOVA >0.05), suggesting a normal activity of
these organs. All the above results reinforce the biosafety of
this formulation of nanocarriers for future clinical transla-
tional practice.
Protein loading
The protein loading content was determined as 11.3 ± 1.0 µg
BSA per mg NCs (1.13 wt%) with an encapsulation efficiency of
46.0 ± 1.4%, the average of six different batches measured. The
Fig. 9 In vitro and in vivo safety of PLGA–SPION NCs (NC-3). (a) Cell viability after exposing to an increasing dose of NCs for 48 h, expressed as a
percentage of untreated cells (control media), determined by MTT assay (n = 3, mean ± SEM); (b) the curve of body weight of the observed mice
throughout the experiment, the naïve group was not treated serving as control (n = 3), the vehicle group received 150 µL of saline (n = 5) and the
NC group received 0.84 mg NCs in 150 µL of saline (n = 5); (c) liver and pancreatic toxicity after 13 days of NC injection based on specific enzyme
levels in plasma: alanine aminotransferase (ALT), alkaline phosphatase (ALK), aspartate aminotransferase (AST) and α-amylase.
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protein loading of 1.13 wt% is much higher than the reported
value (0.03 wt%) of vessel endothelial growth factor loaded
PLGA NCs31 and the EE% is comparable to the PLGA NCs
loaded with neurotrophin-3 (47 ± 2%) or brain-derived neuro-
trophic factor (47 ± 7%).8
Conclusions
By covalently bonding PLGA with small molecules of fluoro-
phores and radioligands as well as by incorporating iron oxide
nanoparticles we propose here chemical synthetic approaches
to transform PLGA NCs into a sensitive, multimodal theranos-
tic platform for drug delivery. We have shown that the size of
PLGA NCs remained unaltered after incorporation or removal
of one or several imaging moieties. We have proposed a
modular approach for capsules with multimodal capacities to
be used at several development phases and investigated by
different imaging modalities including MRI, fluorescence at
different emitting wavelengths (blue and NIR) or 89Zr-labeling
enabled positron emission tomography (PET) imaging. In all
cases, the imaging moieties are chemically attached to the
PLGA and with minimal interaction with the encapsulated
drug thus avoiding leaching and interferences with the thera-
peutic agent.
The theranostic PLGA NCs show no toxicity in vitro or
in vivo. In this regard, the NCs did not affect the viability of
two different human endothelial cells (brain endothelial
cells and CD34+ derived endothelial cells) for concentration
up to 100 μg mL−1. In vivo biosafety was shown based on
the lack of morbidity of mice for 2 weeks after the
systemic NC administration and the fact that none of the bio-
marker enzymes monitored were significantly different
between groups and similar to those measured in non-treated
mice.
Finally, we have shown that the NCs can contain over 1 wt%
of protein in their core achieved at the fabrication level.
Interestingly, PLGA NCs decorated with iron oxide nano-
particles can be exploited for magnetic retention or magnetic
guiding and biodistribution could be modified by using
PEG-PLGA NCs.
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